Novartis AG (Novartis) is an innovative medicines company engaged in the research, development, manufacturing, distribution, marketing, and sale of a broad range of pharmaceutical medicines. It majorly focuses on disease areas such as acute myeloid leukemia; breast cancer; C3 glomerulopathy; chagas disease; chronic myeloid leukemia; covid-19; dry eye disease; elevated lipoprotein; elevated lipoprotein; heart failure; IgA nephropathy; leprosy; lung cancer; malaria; melanoma; migraine; multiple myeloma; multiple sclerosis; neuroendocrine tumors; paroxysmal nocturnal hemoglobinuria; prostate cancer; rare kidney disease; sickle cell disease; and spinal muscular atrophy.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Novartis focuses on innovative research and development (R&D) of medicines. The company's R&D offers product pipelines to deliver transformative medicines to combat diseases. Novartis R&D focuses on multiple therapeutic areas, including cardiovascular, renal, and metabolic diseases, oncology, immunology, and neuroscience. The company established platforms that focus on research areas related to chemistry and biotherapeutics, and advanced platforms, including xRNA, radioligand therapy, and gene and cell therapy, to develop new medicines. The company is investing in AI and other technologies to enhance and accelerate the delivery of innovative medicines. The company’s Biomedical Research Unit is responsible for the discovery and early clinical evaluation of new medicines. It focuses on uncovering biological insights to drive the discovery and development of the next generation of medicines. Furthermore, its Development Unit oversees and executes drug development activities, working collaboratively with the Biomedical Research Unit and other parts of the company. It manages the advanced clinical development of medicines, running large clinical trials and steering the way to regulatory approval and access for patients. The company collaborates with Orionis Biosciences and the University of California, Berkeley, among others, to enhance its drug discovery capabilities. As of December 2025, the company operated research sites in Switzerland and the US. In FY2025, the company spent US$11,200 million on its R&D activities, which as a percentage of revenue, stood at 20.5%, and grew 11.8% YoY. A few of pipeline products in phase III includes AAA617 to treat Metastatic hormone sensitive prostate cancer (mHSPC) and Oligometastatic prostate cancer; AIN457 to treat Giant cell arteritis and Polymyalgia rheumatica; AMG334 to treat Migraine in pediatrics; BAF312 to treat Multiple sclerosis in pediatrics; BYL719 to treat Lymphatic malformations; AAA601 to treat Gastroenteropancreatic neuroendocrine tumors; DAK539 to treat Myelofibrosis; DWH213 to treat Facioscapulohumeral muscular dystrophy; and HTT227 to treat Huntington’s disease, among others. As of December 2025, the company employed 5,720 full-time-equivalent scientists, physicians, and business professionals in its Biomedical Research unit and 13,530 full-time equivalent employees in its Development unit.